| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tamas Tornai, Eszter Palyu, Zsuzsanna Vitalis, Istvan Tornai, David Tornai, Peter Antal-Szalmas, Gary L Norman, Zakera Shums, Gabor Veres, Antal Dezsofi, Gabriella Par, Alajos Par, Peter Orosz, Ferenc Szalay, Peter L Lakatos and Maria Papp |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Research Grant of National Research Development and Innovation Office |
K115818/2015/1 |
| János Bólyai Research Scholarship of Hungarian Academy of Sciences and Tamas Tornai was supported through the New National Excellence Program of the Ministry of Human Capacities |
ÚNKP-16-3 |
|
| Corresponding Author |
Maria Papp, MD, PhD, Institute of Internal Medicine, Department of Gastroenterology, University of Debrecen, Faculty of Medicine, Nagyerdei krt. 98, H-4032 Debrecen, Hungary. papp.maria@med.unideb.hu |
| Key Words |
Primary sclerosing cholangitis; Gut barrier dysfunction; Intestinal fatty acid-binding protein; Anti-F-actin antibody; Anti-gliadin antibody |
| Core Tip |
Importance of gut-liver interaction in the pathogenesis of primary sclerosing cholangitis (PSC) has been certified by a variety of clinical and experimental evidences. Clinical manifestations and progression of the disease are heterogeneous. No reliable biomarkers have been identified to this point that is able to predict the pace of progression. In the present, prospective follow-up study, we evaluated the clinical importance of novel serological markers related to gut barrier function in the prediction of progressive disease course in a cohort of PSC patients. IgA type anti-F-actin antibody was identified as a novel serologic marker during the prognostic work-up of PSC. Presence of anti-F-actin IgA identified PSC patients with progressive disease course and was associated with enhanced mucosal immune response to various microbial antigens and enterocyte damage further highlighting the importance of the gut-liver interaction in PSC. |
| Citation |
Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. World J Gastroenterol 2017; 23(29): 5412-5421 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
